
UroToday.com
@urotoday
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
ID: 21319494
19-02-2009 17:36:50
113,113K Tweet
27,27K Followers
6,6K Following

#ProstateCancer efficacy results from a randomized phase 3 evaluation of transdermal estradiol vs LHRH agonists for androgen suppression in M0 prostate cancer. Presented by Ruth Langley, PhD MRC Clinical Trials Unit at UCL. #ESMO24 written coverage by Zach Klaassen > bit.ly/4d6XNLN
